The IL-7Rα targeted monoclonal antibody, lusvertikimab, has shown preliminary efficacy against ulcerative colitis (66) and IL7Rα+ T cell acute lymphoblastic leukemia (T-ALL) (67). This evidence concerns the gene IL7R and ulcerative colitis.